We're Not Worried About Arcellx's (NASDAQ:ACLX) Cash Burn

Generado por agente de IAWesley Park
lunes, 3 de marzo de 2025, 5:55 am ET1 min de lectura
ACLX--

Alright, let's address the elephant in the room. ArcellxACLX-- (NASDAQ:ACLX) is burning through cash at a rate that might make some investors nervous. But we're not worried, and here's why.

First, let's look at the numbers. Arcellx's net cash flow from operating activities for the year ended December 31, 2023, was -$290.6 million. That's a significant cash burn, but it's important to put it into context. Arcellx is a clinical-stage biotechnology company, which means it's investing heavily in research and development. This is a common trait among biotech companies, and it's reflected in their cash burn rates.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios